Purkiss Capital Advisors LLC Raises Position in Thermo Fisher Scientific Inc. $TMO

Purkiss Capital Advisors LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 52.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 3,455 shares of the medical research company’s stock after acquiring an additional 1,186 shares during the period. Thermo Fisher Scientific makes up 0.8% of Purkiss Capital Advisors LLC’s portfolio, making the stock its 27th largest holding. Purkiss Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,401,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. CBIZ Investment Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. boosted its position in shares of Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the period. Finally, HighMark Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.4%

Shares of TMO opened at $564.49 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market capitalization of $213.16 billion, a price-to-earnings ratio of 32.61, a price-to-earnings-growth ratio of 3.35 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The business’s 50 day simple moving average is $505.57 and its 200-day simple moving average is $454.34.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the business posted $5.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $595.75.

Insider Activity

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,666 shares of company stock worth $13,990,971 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.